DOCSLIB.ORG

Vertex Pharmaceuticals Inc / Ma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vertex Pharmaceuticals Inc / Ma VERTEX PHARMACEUTICALS INC / MA FORM 10-K (Annual Report) Filed 02/15/18 for the Period Ending 12/31/17 Address 50 NORTHERN AVENUE BOSTON, MA, 02210 Telephone 6173416393 CIK 0000875320 Symbol VRTX SIC Code 2834 - Pharmaceutical Preparations Industry Biotechnology & Medical Research Sector Healthcare Fiscal Year 12/31 http://www.edgar-online.com © Copyright 2018, EDGAR Online, a division of Donnelley Financial Solutions. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, a division of Donnelley Financial Solutions, Terms of Use. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________ FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2017 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19319 ____________________________________________ Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 04-3039129 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 50 Northern Avenue, Boston, Massachusetts 02210 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code (617) 341-6100 ____________________________________________ Securities registered pursuant to Section 12(b) of the Exchange Act: Title of Each Class Name of Each Exchange on Which Registered Common Stock, $0.01 Par Value Per Share The NASDAQ Global Select Market Securities registered pursuant to Section 12(g) of the Exchange Act: None ______________________________________________ Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes x No o Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes o No x Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10 K. x Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one): Large accelerated filer x Accelerated filer o Non-accelerated filer o Smaller reporting company o Emerging growth company o (Do not check if a smaller reporting company) If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x The aggregate market value of the registrant’s common stock held by non-affiliates of the registrant (without admitting that any person whose shares are not included in such calculation is an affiliate) based on the last reported sale price of the common stock on June 30, 2017 (the last trading day of the registrant’s second fiscal quarter of 2017 ) was $31.8 billion . As of January 31, 2018 , the registrant had 253,891,984 shares of common stock outstanding. DOCUMENTS INCORPORATED BY REFERENCE Portions of the definitive Proxy Statement for the 2018 Annual Meeting of Shareholders to be held on May 17, 2018 are incorporated by reference into Part III of this Annual Report on Form 10-K. VERTEX PHARMACEUTICALS INCORPORATED ANNUAL REPORT ON FORM 10-K TABLE OF CONTENTS PART I Item 1. Business 1 Directors and Executive Officers of the Registrant 19 Item 1A. Risk Factors 23 Item 1B. Unresolved Staff Comments 44 Item 2. Properties 44 Item 3. Legal Proceedings 44 Item 4. Mine Safety Disclosures 44 PART II Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 45 Item 6. Selected Financial Data 47 Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 48 Item 7A. Quantitative and Qualitative Disclosures About Market Risk 67 Item 8. Financial Statements and Supplementary Data 68 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 68 Item 9A. Controls and Procedures 68 Item 9B. Other Information 71 PART III Item 10. Directors, Executive Officers and Corporate Governance 72 Item 11. Executive Compensation 72 Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 72 Item 13. Certain Relationships and Related Transactions, and Director Independence 72 Item 14. Principal Accountant Fees and Services 72 PART IV Item 15. Exhibits and Financial Statement Schedules 73 Signatures 77 “We,” “us,” “Vertex” and the “Company” as used in this Annual Report on Form 10-K refer to Vertex Pharmaceuticals Incorporated, a Massachusetts corporation, and its subsidiaries. “Vertex,” “KALYDECO ® , ” “ORKAMBI ® ” and “SYMDEKO TM ” are registered trademarks of Vertex. Other brands, names and trademarks contained in this Annual Report on Form 10-K are the property of their respective owners. PART I ITEM 1. BUSINESS OVERVIEW We invest in scientific innovation to create transformative medicines for serious diseases. Our business is focused on developing and commercializing therapies for the treatment of cystic fibrosis, or CF, and advancing our research and development programs in other diseases. Our marketed products are ORKAMBI (lumacaftor in combination with ivacaftor), KALYDECO (ivacaftor) and SYMDEKO (tezacaftor in combination with ivacaftor). Cystic Fibrosis Our goal is to develop treatment regimens that will provide benefits to all patients with CF and will enhance the benefits that currently are being provided to patients taking our medicines. Current Medicines ORKAMBI, KALYDECO and SYMDEKO are collectively approved to treat approximately 45% of the 75,000 CF patients in North America, Europe and Australia. ORKAMBI is approved as a treatment for approximately 28,000 patients who have two copies of the F508del mutation, who we refer to as F508del homozygous patients, in their cystic fibrosis transmembrane conductance regulator, or CFTR , gene. KALYDECO is approved for the treatment of approximately 6,000 CF patients who have the G551D mutation or other specified mutations in their CFTR gene. SYMDEKO was approved by the United States Food and Drug Administration, or FDA, in February 2018 for the treatment of patients with CF twelve years of age and older who are F508del homozygous or who have at least one mutation that is responsive to tezacaftor/ivacaftor, and provides an additional treatment option to CF patients who were already eligible for either ORKAMBI or KALYDECO. We are currently seeking approval from the European Medicines Agency, or EMA, for tezacaftor in combination with ivacaftor. Next-generation CFTR Corrector Triple Combination Regimens In the first quarter of 2018, we selected two next-generation corrector compounds, VX-659 and VX-445, to advance into Phase 3 clinical development as part of separate triple combination regimens. Each of VX-659 and VX-445 have the potential to be combined with both (i) tezacaftor and ivacaftor and (ii) tezacaftor and VX-561, a deuterated version of ivacaftor. We expect to initiate the Phase 3 development program for VX-659 in combination with tezacaftor and ivacaftor in the first half of 2018. In mid-2018, we expect to initiate the Phase 3 development of a once-daily combination of VX-445, tezacaftor and VX-561. Our decision to advance VX-659 and VX-445 was based on available clinical and nonclinical data, including data from an ongoing Phase 2 clinical program, and regulatory discussions are ongoing to finalize the design of the Phase 3 development programs for VX-659 and VX-445. We believe the triple combination regimens we are evaluating could potentially provide benefits to all CF patients who have at least one F508del mutation in their CFTR gene (approximately 90% of all CF patients). This would include (i) the first treatment option that treats the underlying cause of CF for patients who have one copy of the F508del mutation in their CFTR gene and a second mutation in their CFTR gene that results in minimal CFTR function, who we refer to as F508del/Min patients, and (ii) an additional treatment option for patients with CF who are eligible for ORKAMBI, KALYDECO and/or SYMDEKO. Research and Development Programs We have a number of ongoing research and development programs in other diseases that we are conducting independently or in collaboration with third parties. We are developing VX-150 and VX-128 as treatments for pain, co-developing CTX001, an investigational gene editing treatment, for the treatment of beta-thalassemia and sickle cell disease, with CRISPR Therapeutics AG, or CRISPR, and developing VX-210 as a treatment for acute spinal cord injury.
Load more

Recommended publications
  • Curriculum Vitae ALAN MICHAEL GARBER Mailing Address
    Dec 2012 Curriculum Vitae ALAN MICHAEL GARBER Mailing Address: Office of the Provost Massachusetts Hall Harvard Yard Cambridge, MA 02138 Telephone: 617/496-5100 Facsimile number: 617/495-8550 Electronic mail: [email protected] Year of Birth: 1955 Place of Birth: Illinois Marital Status: Married to Anne M. Yahanda, M.D. Education: 9/73-6/76 Harvard College, Cambridge, Massachusetts, A.B. (Economics) 9/76-6/77 Harvard University, Cambridge, Massachusetts, A.M. (Economics) 7/77-10/82 Harvard University, Cambridge, Massachusetts, Ph.D. (Economics) 8/77-6/83 Stanford University School of Medicine, Stanford, California, M.D. Clinical Training: 6/83-6/86 Internship and Residency in Medicine, Brigham and Women's Hospital, Boston, Massachusetts Licensure and Certification: 9/86 American Board of Internal Medicine (Certificate Number 107925) 6/86 California Board of Medical Quality Assurance (G057349) Academic Appointments: 6/83-6/86 Clinical Fellow in Medicine, Harvard Medical School 1/86-6/86 Christopher Walker Research Fellow, Center for Health Policy and Management, John F. Kennedy School of Government, Harvard University 6/86-8/93 Assistant Professor of Medicine, Division of General Internal Medicine, Stanford University School of Medicine 6/86-8/93 Assistant Professor, by courtesy, Department of Economics, Stanford University 9/88-8/93 Assistant Professor, by courtesy, Department of Health Research and Policy, Stanford University School of Medicine 8/93-8/98 Associate Professor of Medicine (tenured), Division of General Internal Medicine, Stanford University School of Medicine 8/93-8/98 Associate Professor, by courtesy, Department of Economics and Department of Health Research and Policy, Stanford University 9/97-8/11 Senior Fellow, Institute for International Studies, Stanford University 9/98-8/11 Henry J.
    [Show full text]
  • Chandra CV May 5, 2021
    Amitabh Chandra 79 JFK Street Harvard Kennedy School of Government Harvard University Cambridge, Massachusetts 02138 email: [email protected] Citizenship United States India (overseas citizen) Degrees, Chronological MA Honorary Degree, Harvard University, 2009 Ph.D Economics, University of Kentucky, 2000 Dissertation: Labor Market Dropouts and the Racial Wage Gap, 1940-1990 MS Economics, University of Kentucky, 1999 BA Economics, University of Kentucky, 1996 Employment July 2020 - present John H. Makin Visiting Scholar American Enterprise Institute July 2018 - present: Henry and Allison McCance Family Professor of Business Administration Faculty Chair, MS/MBA Program in the Life-Sciences Harvard Business School July 2015 – present Ethel Zimmerman Wiener Professor of Public Policy Harvard Kennedy School of Government April 2009 – present Professor and Director of Health Policy Research Harvard Kennedy School of Government October 2009 – present Research Associate National Bureau of Economic Research (NBER) July 2012 - present Panel of Health Advisors Congressional Budget Office ! May 6, 21, p. 1/14 Previous Positions July 2012 - 2014 Visiting Scholar American Enterprise Institute January 2011 - 2012 Special Commissioner Massachusetts Commission on Provider Price Reform December 2011 - 2019 Chair Editor and Editor Review of Economics and Statistics April 2011 - 2016 Consultant Microsoft Research April 2008 - 2015 Associate Editor American Economic Journal: Applied July 2008 - 2012 Co-Editor Journal of Human Resources July 2005
    [Show full text]
  • HARVARD LIBRARY Governance
    HARVARD LIBRARY Administrative Organization CLAUDINE GAY ALAN GARBER Faculty Advisory As of September 2020 Library Edgerley Family Dean of the Provost Council to the Board Faculty of Arts and Sciences Harvard Library Birkhoff Mathematical Library * Botany Libraries * Cabot Science Library * Faculty of Arts and Gutman Library, HGSE MARTHA Ernst Mayr Library * Sciences Alex Hodges WHITEHEAD Fine Arts Library * Martha Whitehead Vice President for Fung Library the Harvard Library Library and Knowledge Services, HKS Harvard Film Archive * Faculty of Arts Baker Library, HBS and University School Leslie Donnell Harvard-Yenching Library * and Sciences Librarian; Libraries Debra Wallace Houghton Library * Libraries Roy E. Larsen Harvard Law School Library Lamont Library * Librarian Andover-Harvard Jocelyn Kennedy Loeb Music Library * for the Faculty of Theological Library, HDS Physics Research Library * Arts and Sciences Douglas Gragg Countway Library, HMS Robbins Library of Philosophy Elaine Martin Tozzer Library * Frances Loeb Library, GSD Widener Library * Ann Whiteside Schlesinger Library, Radcliffe Institute Wolbach Library Marilyn Dunn * Harvard College Library FRANZISKA FREY THOMAS HYRY ELIZABETH KIRK MEGAN STY SNYDMAN KIM VAN SAVAGE VAUGHN WATERS SUZANNE WONES LAURA WOOD Chief of Staff and Florence Associate SNIFFIN- Managing Director Human Resources Director of Associate Associate Senior Advisor for Fearrington University Librarian MARINOFF Library Technology Director Administration and University Librarian University Librarian University
    [Show full text]
  • Annual Report 2017 2017 HUTCHINS CENTER for AFRICAN & AFRICAN AMERICAN RESEARCH
    ANNUAL REPORT Annual Report 2017 2017 HUTCHINS CENTER FOR AFRICAN & AFRICAN AMERICAN RESEARCH Hutchins Center for African & African American Research Harvard University 104 Mount Auburn Street, 3R Cambridge, MA 02138 617.495.8508 Phone 617.495.8511 Fax HARVARD [email protected] HutchinsCenter.fas.harvard.edu Facebook.com/HutchinsCenter UNIVERSITY Twitter.com/HutchinsCenter 17070002_Cvr.indd 1 7/7/17 4:14 PM Annual Report 2017 4 12 Letter from the Director 15 Highlights of the Year 29 Flagships of the Hutchins Center 75 A Synergistic Hub of Intellectual Fellowship 91 Annual Lecture Series 94 Archives, Manuscripts, and Collections 96 Research Projects and Outreach 104 Our Year in Events 110 Staff 112 Come and Visit Us Harvard University 17070002_Guts.indd 2 7/7/17 6:32 PM 29 44 54 58 Project on Race, Class 64 & Cumulative Adversity at the Hutchins Center Harvard University 65 67 70 71 73 74 17070002_Guts.indd 3 7/7/17 6:32 PM Director Henry Louis Gates, Jr. Executive Director Abby Wolf The Hutchins Center for African & African American Research is fortunate to have the support of Harvard University President Drew Gilpin Faust, Provost Alan M. Garber, Dean of the Faculty of Arts and Sciences Michael D. Smith, Dean of Social Science Claudine Gay, Administrative Dean for Social Science Beverly Beatty, and Senior Associate Dean for Faculty Development Laura Gordon Fisher. What we are able to accomplish at the Hutchins Center would not be possible without their generosity and engagement. Glenn H. Hutchins, Chair, National Advisory Board. Henry Louis Gates, Jr. and Abby Wolf.
    [Show full text]
  • David M. Cutler Department of Economics Harvard University 226
    David M. Cutler Department of Economics Harvard University 226 Littauer Center - 1805 Cambridge Street Cambridge, MA 02138 Phone: (617) 496-5216 [email protected] Website Employment 2005-: Otto Eckstein Professor of Applied Economics, Department of Economics and Kennedy School of Government, Harvard University 2014-2019: Harvard College Professor, Harvard University 2003-2008: Social Sciences Dean, Faculty of Arts and Sciences, Harvard University 1997-2005: Professor of Economics, Department of Economics and Kennedy School of Government, Harvard University 1995-1997: John L. Loeb Associate Professor of Social Sciences, Harvard University 1993: On leave as Senior Staff Economist, Council of Economic Advisers and Director, National Economic Council 1991-1995: Assistant Professor of Economics, Harvard University Other Affiliations Academic and Policy Advisory Board, Kyruss, Incorporated National Advisory Board, Firefly Board Member, Center for Healthcare Transparency Consultant, Mathematica Policy Research, Inc. Consultant, Mercer Health & Benefits, LLC Fellow, Employee Benefit Research Institute Litigation. Retained by counsel for plaintiffs to provide expert services in pending litigation involving opioid pharmaceuticals. Member, Institute for Research on Poverty Member, Institute of Medicine Member, National Academy of Social Insurance Research Associate, National Bureau of Economic Research, Aging, Health Care, Public Economics, and Productivity programs Scientific Advisory Board, Alliance for Aging Research Scientific Advisory Board,
    [Show full text]
  • VERTEX PHARMACEUTICALS INCORPORATED (Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under §240.14a-12 VERTEX PHARMACEUTICALS INCORPORATED (Name of Registrant as Specified In Its Charter) Payment of Filing Fee (Check the appropriate box): No fee required. Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: Fee paid previously with preliminary materials. Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: Dear Shareholders: 2019 was a remarkable year for Vertex as all parts of our business - research, development, commercial and business development - performed at exceptional levels.
    [Show full text]
  • Alan M. Garber, Provost of Harvard University
    Harvard School of Public Health | Alan M. Garber, Provost of Harvard University BETTY Good afternoon, and welcome to the Voices in Leadership series. This program focuses on the nexus of science JOHNSON: and leadership to create positive change in the world of public health. I am Betty Johnson, and I have the privilege to direct and introduce this program. Our guest today could be called a Renaissance man of academia. When he was a university freshman, he said, and I quote, "I was a reluctant and ambivalent pre-med student. But after being exposed to an economics course, I switched my major to a concentration from biochemistry to economics," end quote. This switch in plan ultimately led to a PhD in economics from Harvard, while at the same time he was earning an MD degree from Stanford. Today, Dr. Alan Garber's career combines both interests. And it is no surprise that this combination of a love for science and economics eventually landed him a role as university provost. But not as any university provost, our university provost. In a political climate in Washington, DC, where robust research funded is under threat, Dr. Alan Garber is perfectly suited to lead Harvard's efforts to ensure the research pipeline remains strong. His intellectual interests are far reaching. At Stanford, he was a fellow in both the Freeman Spogli Institute for International Studies and the Stanford Institute for Economic Policy Research. He also served as director for Stanford Center for Health Policy and Center for Primary Care and Outcomes Research at Stanford School of Medicine.
    [Show full text]
  • Learning's Leading Edges
    JOHN HARVARD'S JOURNAL They point to the checks and balances Learning’s Leading Edges each person’s characteristic style. There used to ensure that research is under- is no evidence, she asserted, supporting taken responsibly, and that each experi- The harvard initiative on Learning the idea that such matching influences ment is evaluated not only on its sci- and Teaching (HILT), unveiled in Octo- learning outcomes. entific merits but also on criteria such ber, was inaugurated in a symposium on Nobel laureate in physics Carl Wie- as whether the research uses the right February 3. More than 300 participants man, a pioneer in effective science educa- species and the fewest possible number convened from all Harvard’s faculties— tion and associate director of science at of animals, and is designed to cause the principally senior professors and deans— the White House Office of Science and least amount of suffering. For certain sci- plus invited panelists with special ex- Technology Policy, noted that although entific questions, such as developing a pertise in the field. HILT is the fruit of a much is known (from cognitive psychol- vaccine to prevent HIV or trying to solve $40-million gift from Gustave M. Hauser, ogy, brain science, and college classroom major problems in neurodegenerative J.D. ’53, and his wife, Rita E. Hauser, L studies) about thinking and learning, disease, other animal models are a poor ’58, who attended the symposium and this knowledge is almost never applied approximation of a human being. Pri- participated actively during the question to teaching techniques. He cited a few re- mates are “only used when lower animals periods (see “Investing in Learning and search results that are well established: won’t work, and they’re used in some Teaching,” January-February, page 60).
    [Show full text]
  • January 16, 2020 Fong Auditorium, Boylston Hall Agenda
    FAS Administrators’ Town Hall January 16, 2020 Fong Auditorium, Boylston Hall Agenda Connect with FAS Colleagues Ticknor Lounge Welcome, Introductions, and Updates Leslie Kirwan Harvard Library: from Collections to Martha Whitehead Connections Financial Updates Leslie Kirwan, Jay Herlihy HUIT Charles Kling, Maria Apse, Alan Wolf, Kyle Shachmut Administrative Systems Palooza Mary Ann Bradley Closing / Q & A Session Leslie Kirwan Page 2 Welcome, Introductions, and Updates Leslie Kirwan Dean for Administration and Finance Harvard Library: from Collections to Connections Martha Whitehead Vice President, Roy E. Larsen Librarian for the Faculty of Arts and Sciences Harvard Library and Open Knowledge: Collections and Connections Martha Whitehead, Vice President for the Harvard Library and Roy E. Larsen Librarian for the Faculty of Arts and Sciences FAS Administrators’ Town Hall, January 16, 2020 Outline 1. Research libraries in a global knowledge commons 2. Harvard Library a) Overview b) Sample services c) Key current priorities 3. Discussion Research libraries in a global knowledge commons Our Shared Goal: Collaboratively develop a global knowledge commons for the benefit of our user communities Data at the core, surrounded by enabling layers of: • policy • distributed infrastructure • services that facilitate user engagement with data Data at the Core: Developing a Holistic Vision We have distinct associations, initiatives and parts of our organizations focused on these four different forms of data, but they have similar concerns: • Acquisition
    [Show full text]
  • Overseers' Committee to Visit the Harvard Library
    Meeting of the OVERSEERS’ COMMITTEE TO VISIT THE HARVARD LIBRARY March 21–22, 2017 MEETING OF THE OVERSEERS’ COMMITTEE TO VISIT THE HARVARD LIBRARY March 21-22, 2017 Table of Contents I. *Introduction a. Overseers’ Committee to Visit the Harvard Library, Members, 2016-2018 b. Overseers’ Committee to Visit the Harvard Library, Member Bios c. Meeting Agenda d. Presenter Bios e. Campus Map II. *Harvard University: Strategic Directions and Priorities a. Mission and Goals III. Harvard Library Overview a. *Harvard Library Visiting Committee Report, 2014 b. *Harvard Library Management Response, 2015 c. *Memorandum to the Visiting Committee d. *Closing the Book on the Transition: The Harvard Library e. *Budget Overview f. *Harvard Library Allocation Model g. *Objectives in Action 2016-2021 h. *Harvard Library Administrative Organization i. *Harvard Library Committee Structure j. Standing Committee Annual Report k. Report of the Harvard Library Committee System Assessment Working Group IV. Harvard Library’s Digital Strategy a. *Harvard Library Digital Strategy 1.0 b. Research Data Management at Harvard Library c. *Embracing the Library’s Digital Future d. Harvard Law School Library Innovation Lab e. Baker 3.0 f. Charlie Archive at the Harvard Library g. Colonial North America at Harvard Library h. Uncovering Harvard Library’s Hidden Collections i. Web Archiving j. Email Archiving k. The Dataverse Project l. *Strategic Conversations m. *Research, Teaching, and Learning (RTL) Event Flyers V. Lunch with the Library Board and Faculty Advisory Council (FAC) a. FAC Meeting Minutes b. *FAC, Academic Year 2016 c. *Library Board, Academic Year 2016 VI. Collective Collections a. *Summary of Harvard’s Relations and Aspirations b.
    [Show full text]
  • A Home for Innovation and Entrepreneurship at Harvard
    A Home for Innovation and Entrepreneurship at Harvard Welcome. The Harvard Innovation Labs are a vibrant, cross-disciplinary ecosystem for the Harvard community to explore innovation and entrepreneurship while building deeper connections. The Labs are an excellent example of the One Harvard vision and a leading catalyst for the Allston Science and Enterprise District. The Harvard Innovation Labs began in 2011 with the opening of the i-lab, expanded in 2014 when the Launch Lab opened its doors, and will continue to grow in both breadth and depth with future resources, including a Wet Lab which comes online in 2016 (projected). The Harvard i-lab The i-lab is the central component of the Harvard Innovation Labs ecosystem. It is an educational collaborative for all current Harvard students from any Harvard school to explore innovation and entrepreneurship at any stage. It provides open co- working space, a vibrant community of peer and mentor support, experiential programming, and a 12-week Venture Incubation Program helping student teams take their ideas as far as they can go. The Harvard Launch Lab The Launch Lab is a critical extension of the growing Harvard Innovation Labs ecosystem. It provides eligible Harvard alumni leading high-potential early- stage startups with a curated community including collaborative co-working space, business building programming, and access to i-lab advisors and mentors. It fosters continued connection between alumni, current students and the Harvard community as a whole. Moving Further, Faster There has never been a better time to be a part of innovation at Harvard. The Harvard Innovation Labs have an unprecedented opportunity to continue to shape cross-disciplinary collaboration at Harvard and serve as a catalyst to solving society’s most pressing needs through innovation and entrepreneurship.
    [Show full text]
  • CHART: Harvard Library Oversight, Governance, and Committees
    HARVARD LIBRARY Administrative Organization CLAUDINE GAY ALAN GARBER Faculty Advisory Library As of May 2021 Edgerley Family Dean of the Provost Council to the Board Faculty of Arts and Sciences Harvard Library Birkhoff Mathematical Library * Botany Libraries * Cabot Science Library * Faculty of Arts and Gutman Library, HGSE MARTHA Ernst Mayr Library * Sciences Alex Hodges WHITEHEAD Fine Arts Library * Martha Whitehead Vice President for Fung Library the Harvard Library Library and Knowledge Services, HKS Harvard Film Archive * Faculty of Arts Baker Library, HBS and University School Christina Sirois Harvard-Yenching Library * and Sciences Librarian; Libraries Debra Wallace Houghton Library * Libraries Roy E. Larsen Harvard Law School Library Lamont Library * Librarian for the Andover-Harvard Jocelyn Kennedy Loeb Music Library * Faculty of Arts Theological Library, HDS Physics Research Library * and Sciences Douglas Gragg Countway Library, HMS Robbins Library of Philosophy Elaine Martin Tozzer Library * Frances Loeb Library, GSD Widener Library * Ann Whiteside Schlesinger Library, Radcliffe Institute Wolbach Library Ellen Shea * Harvard College Library FRANZISKA FREY THOMAS HYRY ELIZABETH KIRK JEROME OFFORD STU SNYDMAN KIM VAN SAVAGE VAUGHN WATERS SUZANNE WONES LAURA WOOD Chief of Staff and Associate Associate Associate Associate Human Resources Director of Associate Associate Senior Advisor for University Librarian University Librarian University Librarian University Librarian Director Administration and University Librarian University
    [Show full text]